Preview

Health and Ecology Issues

Advanced search

Clinical significance of the T(-344)C polymorphism of the aldosterone synthase gene (CYP11B2) in the prognosis of cardiorenal syndrome in diabetes mellitus

https://doi.org/10.51523/2708-6011.2022-19-4-07

Abstract

Objective. To evaluate the role of the T(-344)C polymorphism of CYP11B2 gene in the development of cardiorenal syndrome (CRS) in diabetes mellitus (DM).

Materials and methods. 270 patients with type 1 and type 2 diabetes aged over 25 years were examined. All patients underwent molecular genetic analysis using deoxyribonucleic acid isolated from whole venous blood.

Results. The TT genotype was associated with the risk of developing CRS manifestations such as left ventricular hypertrophy (odds ratio (OR) 2.64; 95% CI (0.93–4.19), chronic heart failure (OR 4.26; 95% CI (2.26 - 8.06), subclinical atherosclerosis (OR 4.04; 95% CI (1.89 - 8.58), chronic kidney disease (CKD) (OR 10.77; 95% CI (3.56 - 32.61), and the CT genotype (OR 3.28; 95% CI (1.02 – 10.59) with CKD risk..

Conclusion. There are pathogenetic associations between renin-angiotensin-aldosterone system, cardiovascular complications and a decrease of renal function. Further research is needed for a deep understanding of the complex pathogenetic mechanisms of the development and progression of cardiovascular and renal pathology.

About the Authors

V. N. Vasilkova
Gomel State Medical University
Belarus

Volha N. Vasilkova, Candidate of Medical Sciences,
Associate Professor of the Department of Internal Diseases №1 with a course of Endocrinology 

Gomel



I. Yu. Pchelin
St. Petersburg State University
Russian Federation

Ivan Yu. Pchelin, Candidate of Medical Sciences, Associate Professor performing clinical work at the Department of Faculty Therapy

St. Petersburg



Ya. A. Borovets
Gomel State Medical University
Belarus

Yana A. Borovets, Assistant of the Department of Internal Diseases №1 with a course of Endocrinology

Gomel



I. A. Vasukhina
Republican Research Center for Radiation Medicine and Human Ecology
Belarus

Irina A. Vasukhina, Endocrinologist 

Gomel 



T. V. Mokhort
Belarusian State Medical University
Belarus

Tatsiana V. Mokhort, Doctor of Medical Sciences,
Professor, Head of the Department of Endocrinology

Minsk 



References

1. Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. Curr Cardiol Rep. 2019;21(6):45. DOI: https://doi.org/10.1007/s11886-019-1133-9

2. Poznyak AV, Bharadwaj D, Prasad G, Grechko AV, Sazonova MA, Orekhov AN. Renin-Angiotensin System in Pathogenesis of Atherosclerosis and Treatment of CVD. Int J Mol Sci. 2021;22;22(13):6702. DOI: https://doi.org/10.3390/ijms22136702

3. Böckmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer DC, Heineke J, Haffner D, Leifheit-Nestler M. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis. Int J Mol Sci. 2019;18;20(18):4634. DOI: https://doi.org/10.3390/ijms20184634

4. Pattacini L, Casali B, Boiardi L, et al. Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF- kappaB pathway. Rheumatology (Oxford). 2007 Aug;46(8):1252-1257. DOI: https://doi.org/10.1093/rheumatology/kem092

5. Seredyuk V. Role of aldosterone, mitogenic growth factors, apoptosis inducers and pulmonary arterial hypertension in the formation and progression of chronic pulmonary heart disease. Pharm Innovat J. 2013;2(5):36-40.

6. Naccarelli GV, Filippone EJ, Foy A. Do Mineralocorticoid Receptor Antagonists Suppress Atrial Fibrillation/Flutter? J Am Coll Cardiol. 2021;78(2):153-155. DOI: https://doi.org/10.1016/j.jacc.2021.04.080

7. Lu WH, Bayike M, Liu JW, Wang S, et al. Association between aldosterone synthase (CYP11B2) -344C/T polymorphism and atrial fibrillation among Han and Kazak residents of the Xinjiang region. Int J Clin Exp Med. 2015;8(4):5513-5519.

8. Abdel Ghafar MT. Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population. Clin Exp Hypertens. 2019;41(8):779-786. DOI: https://doi.org/10.1080/10641963.2018.1557679

9. Elgazzaz M, Lazartigues E. Epigenetic modifications of the renin-angiotensin system in cardiometabolic diseases. Clin Sci (Lond). 2021;135(1):127-142. DOI: https://doi.org/10.1042/CS20201287

10. Abdel Ghafar MT. Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population. Clin Exp Hypertens. 2019;41(8):779-786. DOI: https://doi.org/10.1080/10641963.2018.1557679

11. Nishiyama A, Kobori H. Independent regulation of reninangiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018;22(6):1231-1239. DOI: https://doi.org/10.1007/s10157-018-1567-1

12. Shrestha A, Che RC, Zhang AH. Role of Aldosterone in Renal Fibrosis. Adv Exp Med Biol. 2019;1165:325-346. DOI: https://doi.org/10.1007/978-981-13-8871-2_15

13. Svenningsen P, Hinrichs GR, Zachar R, Ydegaard R, Jensen BL. Physiology and pathophysiology of the plasminogen system in the kidney. Pflugers Arch. 2017 Nov;469(11):1415- 1423. DOI: https://doi.org/10.1007/s00424-017-2014-y

14. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. DOI: https://doi.org/10.1016/S2213-8587(17)30319-4

15. Byrd JB, Auchus RJ, White PC. Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. J Investig Med. 2015;63(7):862-866. DOI: https://doi.org/10.1097/JIM.0000000000000220

16. Yin C, Gu W, Gao Y, Li Z, Chen X, Li Z, Wen S. Association of the -344T/C polymorphism in aldosterone synthase gene promoter with left ventricular structure in Chinese Han: A meta-analysis. Clin Exp Hypertens. 2017;39(6):562-569. DOI: https://doi.org/10.1080/10641963.2017.1291660

17. Dai B, David V, Martin A, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012;7:e44161. DOI: https://doi.org/10.1371/journal.pone.0044161

18. Prud’homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front Aging. 2022;12(3):931331. DOI: https://doi.org/10.3389/fragi.2022.93133

19. Imazu M, Takahama H, Asanuma H, et al. Pathophysiological impact of serum fibroblast growth factor 23 in patients with non-ischemic cardiac disease and early chronic kidney disease. Am J Phys. 2014;307:H1504-1511. DOI: https://doi.org/10.1152/ajpheart.00331.2014

20. Zhang B, Umbach AT, Chen H, et al. Up-regulation of FGF23 release by aldosterone. Biochem Biophy Res Commun. 2016;470:384-390. DOI: https://doi.org/10.1016/j.bbrc.2016.01.034

21. Syed SB, Qureshi MA. Association of aldosterone and cortisol with cardiovascular risk factors in prehypertension stage. Int J Hypertens. 2012;2012:906327. DOI: https://doi.org/10.1155/2012/906327

22. Sjöberg B, Anderstam B, Suliman M, Alvestrand A. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis. 2006;47(1):60-71. DOI: https://doi.org/10.1053/j.ajkd.2005.09.032

23. Karolczak K, Kubalczyk P, Glowacki R, Pietruszynski R, Watala C. Aldosterone modulates blood homocysteine and cholesterol in coronary artery disease patients - a possible impact on atherothrombosis? Physiol Res. 2018;4;67(2):197-207. DOI: https://doi.org/10.33549/physiolres.933668


Review

For citations:


Vasilkova V.N., Pchelin I.Yu., Borovets Ya.A., Vasukhina I.A., Mokhort T.V. Clinical significance of the T(-344)C polymorphism of the aldosterone synthase gene (CYP11B2) in the prognosis of cardiorenal syndrome in diabetes mellitus. Health and Ecology Issues. 2022;19(4):48-55. (In Russ.) https://doi.org/10.51523/2708-6011.2022-19-4-07

Views: 289


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2220-0967 (Print)
ISSN 2708-6011 (Online)